Vanguard Capital Management’s Perspective Therapeutics CATX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.1M Sell
4,407,246
-29,326
-0.7% -$88.9K ﹤0.01% 2648
2026
Q2
$15.1M Buy
4,436,572
+57,616
+1% +$218K ﹤0.01% 2594
2026
Q1
$18.3M Buy
+4,378,956
New +$18.5M ﹤0.01% 2396

Other funds holding CATX

Vanguard Capital Management's CATX Position: Q3 2026 in Review

Vanguard Capital Management reduced its Perspective Therapeutics (CATX) stake by 0.66% in Q3 2026, selling an estimated $88.9K and leaving 4,407,246 shares worth $12.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2648.

Vanguard Capital Management first reported a position in CATX in Q1 2026 and has held it in 3 quarters since. The position peaked at $18.3M in Q1 2026. 120 funds tracked by Wall St. Rank hold CATX as of Q3 2026.

  • Vanguard Capital Management held 4,407,246 shares of Perspective Therapeutics worth $12.1M as of Q3 2026.
  • Vanguard Capital Management sold 29,326 Perspective Therapeutics shares in Q3 2026, an estimated $88.9K.
  • Perspective Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2648 holding.
  • Vanguard Capital Management first reported a position in Perspective Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Perspective Therapeutics position peaked at $18.3M in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.